Revista: The European Journal of Health Economics
Resumen: Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients’ quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization. To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Cómo citar: Hidalgo-Vega, Á., Ramos-Goñi, J. M., & Villoro, R. (2014). Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. The European Journal of Health Economics, 15(9), 917-925.